GLIPIZIDE AND METFORMIN HYDROCHLORIDE Drug Patent Profile

Which patents cover Glipizide And Metformin Hydrochloride, and what generic alternatives are available?

Glipizide And Metformin Hydrochloride is a drug marketed by Epic Pharma Llc, Heritage, Novitium Pharma, Sun Pharm Inds Inc, Teva Pharms, and Zydus Pharms Usa Inc. and is included in six NDAs.

The generic ingredient in GLIPIZIDE AND METFORMIN HYDROCHLORIDE is glipizide; metformin hydrochloride. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the glipizide; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Glipizide And Metformin Hydrochloride

A generic version of GLIPIZIDE AND METFORMIN HYDROCHLORIDE was approved as glipizide; metformin hydrochloride by EPIC PHARMA LLC on October 27^th, 2005.

Summary for GLIPIZIDE AND METFORMIN HYDROCHLORIDE

US Patents:	0
Applicants:	6
NDAs:	6
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
DailyMed Link:	GLIPIZIDE AND METFORMIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for GLIPIZIDE AND METFORMIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Catholic University of Korea	Phase 4
Merck Sharp & Dohme Corp.	Phase 4
Bristol-Myers Squibb	Phase 4

See all GLIPIZIDE AND METFORMIN HYDROCHLORIDE clinical trials

Pharmacology for GLIPIZIDE AND METFORMIN HYDROCHLORIDE

Drug Class

Biguanide Sulfonylurea

US Patents and Regulatory Information for GLIPIZIDE AND METFORMIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	077507-001	Oct 27, 2005	AB	RX	No	No
Zydus Pharms Usa Inc	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	078905-003	Jan 31, 2011	AB	RX	No	No
Novitium Pharma	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	078083-001	Apr 12, 2007		DISCN	No	No

Market Dynamics and Financial Trajectory for Glipizide and Metformin Hydrochloride

Last updated: February 20, 2026

What Are the Market Drivers for Glipizide and Metformin Hydrochloride?

These drugs are primarily prescribed for type 2 diabetes mellitus. They benefit from a growing global prevalence of diabetes, driven by lifestyle factors, aging populations, and increased screening efforts. Market growth is further propelled by dependency on branded and generic formulations, governmental health policies encouraging diabetes management, and the expansion of healthcare infrastructure in emerging markets.

Major factors influencing market growth include:

• Increasing diabetic patient population: Estimated to reach 700 million globally by 2045 [1].
• Adoption of combination therapies: Use of Glipizide with Metformin as first-line treatment.
• Generic drug expansion: Patent expirations of branded formulations open access to generics.
• Regulatory shifts: Favorable policies in countries like India and China promote production and importation.
• Insulin companion market: Increasing use as adjunct therapy amplifies demand.

How Do Market Segments Break Down?

The market comprises branded and generic formulations, with key distinctions:

Segment	Market Share	Key Players	Growth Drivers
Branded	40%	Novo Nordisk, Sanofi	R&D investments; brand loyalty
Generics	60%	Local manufacturers, Mylan, Teva	Patent expiry; cost-sensitive markets

Regionally, North America holds the largest market share, driven by high prevalence and healthcare spending. Asia-Pacific emerges rapidly due to expanding healthcare infrastructure and high diabetes incidence.

What Are the Key Financial Trends?

Revenue Trends

Global revenue for oral antidiabetic drugs, including Glipizide and Metformin, was approximately USD 20 billion in 2022, with a compound annual growth rate (CAGR) of 6% projected from 2023-2030 [2].

Pricing Dynamics

Generic formulations retail from USD 0.05 to USD 0.20 per tablet, depending on jurisdiction and manufacturer. Branded drugs fetch higher prices, often exceeding USD 1 per tablet.

Patent and Market Exclusivity

Metformin's patent expired in most jurisdictions by 2000, increasing generic competition. Glipizide's patent expired in the early 2000s, contributing to the surge in generic options. Innovative combination formulations, such as fixed-dose combinations (FDCs), have secured patent protection, extending market exclusivity for some products.

Investment in R&D

Major companies invest approximately USD 200 million annually in antidiabetic research, focusing on novel formulations and combination therapies.

How Does Competition Shape the Market?

Intense generic competition constrains pricing and margins. Larger pharmaceutical firms focus on value-added formulations, such as sustained-release versions and fixed-dose combinations. Market dynamics favor localized manufacturing to meet cost pressures and regulatory barriers.

What Are the Emerging Opportunities?

Growth potential lies in:

• Developing novel fixed-dose combinations.
• Expanding presence in emerging markets.
• Incorporating digital health monitoring tools.
• Streamlining manufacturing processes to reduce costs.

What Challenges Could Affect Financial Performance?

Major hinderances include:

• Stringent regulatory environments.
• Pricing pressures from healthcare payers.
• Shifts toward newer drug classes, such as SGLT2 inhibitors.
• Patent litigations and patent cliff effects.

Summary of Key Financial Insights

Aspect	Details
Global Market Size (2022)	USD 20 billion (oral antidiabetics)
Expected CAGR (2023-2030)	6%
Major Revenue Sources	North America (~45%); Asia-Pacific (~25%)
Patent Status	Expired for Glipizide and Metformin; active for some combination products
Pricing Range	USD 0.05–1.00 per tablet

Key Takeaways

The market for Glipizide and Metformin hydrochloride remains robust due to the high and rising prevalence of type 2 diabetes. Patent expirations have increased generic availability, leading to price competition. Growth opportunities exist in combination therapies and expanding geographical markets, especially in emerging economies. Competition and regulatory pressures are primary challenges affecting revenue streams.

FAQs

1. How has patent expiration affected market prices for Glipizide and Metformin?
   Patent expirations led to increased generic competition, reducing prices and increasing accessibility.

2. What is the outlook for branded versus generic formulations?
   Generics dominate market share, while branded drugs focus on sustained-release and combination therapies for differentiation.

3. Are new formulations impacting traditional markets?
   Yes, fixed-dose combinations and extended-release formulations see increased adoption, partially displacing older versions.

4. How significant is the role of emerging markets?
   Emerging markets contribute a growing share of sales, with faster adoption driven by rising diabetes prevalence and cost sensitivity.

5. What are potential strategic moves for market players?
   Investing in combination formulations, expanding production capacity in emerging markets, and integrating digital health solutions.

References

[1] International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th Edition.
[2] Grand View Research. (2023). Oral Antidiabetic Drugs Market Size, Share & Trends Analysis Report.